Search Results

There are 5587 results for: content related to: Diagnostic assays for identification of anaplastic lymphoma kinase-positive non–small cell lung cancer

  1. You have free access to this content
    Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein

    British Journal of Pharmacology

    Volume 166, Issue 5, July 2012, Pages: 1669–1683, Wen-jing Zhou, Xu Zhang, Chao Cheng, Fang Wang, Xiao-kun Wang, Yong-ju Liang, Kenneth Kin Wah To, Wang Zhou, Hong-bing Huang and Li-wu Fu

    Article first published online : 21 JUN 2012, DOI: 10.1111/j.1476-5381.2012.01849.x

  2. Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase–Rearranged Non–Small Cell Lung Cancer

    Clinical Pharmacology & Therapeutics

    Volume 95, Issue 1, January 2014, Pages: 15–23, B Solomon, KD Wilner and AT Shaw

    Article first published online : 19 DEC 2013, DOI: 10.1038/clpt.2013.200

  3. Targeting ALK Rearrangements

    Lung Cancer, Fourth Edition

    Justin F. Gainor, Alice T. Shaw, Pages: 541–556, 2014

    Published Online : 4 APR 2014, DOI: 10.1002/9781118468791.ch35

  4. You have full text access to this Open Access content
    Echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: Molecular and clinical aspects

    Cancer Science

    Volume 103, Issue 8, August 2012, Pages: 1391–1396, Isamu Okamoto and Kazuhiko Nakagawa

    Article first published online : 17 JUN 2012, DOI: 10.1111/j.1349-7006.2012.02327.x

  5. You have free access to this content
    ALK-positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options

    Cancer

    Volume 120, Issue 16, August 15, 2014, Pages: 2392–2402, Conor E. Steuer and Suresh S. Ramalingam

    Article first published online : 22 MAY 2014, DOI: 10.1002/cncr.28597

  6. You have full text access to this OnlineOpen article
    Complex renal cysts associated with crizotinib treatment

    Cancer Medicine

    Volume 4, Issue 6, June 2015, Pages: 887–896, Patrick Schnell, Cynthia H. Bartlett, Benjamin J. Solomon, Vanessa Tassell, Alice T. Shaw, Tommaso de Pas, Soo-Hyun Lee, Geon Kook Lee, Kaoru Tanaka, Weiwei Tan, Yiyun Tang, Keith D. Wilner, Allan Safferman and Ji-Youn Han

    Article first published online : 10 MAR 2015, DOI: 10.1002/cam4.437

  7. You have free access to this content
    Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

    International Journal of Cancer

    Volume 134, Issue 6, 15 March 2014, Pages: 1484–1494, Seng Chuan Tang, Luan N. Nguyen, Rolf W. Sparidans, Els Wagenaar, Jos H. Beijnen and Alfred H. Schinkel

    Article first published online : 3 OCT 2013, DOI: 10.1002/ijc.28475

  8. You have free access to this content
    Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer

    Cancer

    Volume 118, Issue 21, 1 November 2012, Pages: 5302–5309, Andrew J. Weickhardt, Micol S. Rothman, Smita Salian-Mehta, Katja Kiseljak-Vassiliades, Ana B. Oton, Robert C. Doebele, Margaret E. Wierman and D. Ross Camidge

    Article first published online : 4 APR 2012, DOI: 10.1002/cncr.27450

  9. You have full text access to this OnlineOpen article
    Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK

    Cancer Medicine

    Volume 4, Issue 7, July 2015, Pages: 953–965, Diletta Fontana, Monica Ceccon, Carlo Gambacorti-Passerini and Luca Mologni

    Article first published online : 26 FEB 2015, DOI: 10.1002/cam4.413

  10. You have full text access to this OnlineOpen article
    Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen

    Chemical Biology & Drug Design

    Volume 78, Issue 6, December 2011, Pages: 999–1005, Sen Zhang, Frank Wang, Jeffrey Keats, Xiaotian Zhu, Yaoyu Ning, Scott D. Wardwell, Lauren Moran, Qurish K. Mohemmad, Rana Anjum, Yihan Wang, Narayana I. Narasimhan, David Dalgarno, William C. Shakespeare, Juan J. Miret, Tim Clackson and Victor M. Rivera

    Article first published online : 31 OCT 2011, DOI: 10.1111/j.1747-0285.2011.01239.x

  11. You have free access to this content
    Heart rate decrease during crizotinib treatment and potential correlation to clinical response

    Cancer

    Volume 119, Issue 11, 1 June 2013, Pages: 1969–1975, Sai-Hong Ignatius Ou, Wilson P. Tong, Michele Azada, Christina Siwak-Tapp, Joni Dy and Jonathan A. Stiber

    Article first published online : 15 MAR 2013, DOI: 10.1002/cncr.28040

  12. You have free access to this content
    Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization–positive nonsmall cell lung cancer

    Cancer

    Volume 118, Issue 18, 15 September 2012, Pages: 4486–4494, D. Ross Camidge, Mariana Theodoro, DeLee A. Maxson, Margaret Skokan, Tara O'Brien, Xian Lu, Robert C. Doebele, Anna E. Barón and Marileila Varella-Garcia

    Article first published online : 26 JAN 2012, DOI: 10.1002/cncr.27411

  13. Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects

    The Journal of Clinical Pharmacology

    Volume 55, Issue 1, January 2015, Pages: 104–113, Huiping Xu, Melissa O'Gorman, Tanya Boutros, Nicoletta Brega, Constantino Kantaridis, Weiwei Tan and Akintunde Bello

    Article first published online : 10 JUL 2014, DOI: 10.1002/jcph.356

  14. You have free access to this content
    Native and rearranged ALK copy number and rearranged cell count in non–small cell lung cancer

    Cancer

    Volume 119, Issue 22, 15 November 2013, Pages: 3968–3975, D. Ross Camidge, Margaret Skokan, Porntip Kiatsimkul, Barbara Helfrich, Xian Lu, Anna E. Barón, Nathan Schulte, DeLee Maxson, Dara L. Aisner, Wilbur A. Franklin, Robert C. Doebele and Marileila Varella-Garcia

    Article first published online : 10 SEP 2013, DOI: 10.1002/cncr.28311

  15. You have full text access to this Open Access content
    Sufficiency of Single-Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Cancer Patients: Lessons from the Clinical Development of Crizotinib

    Clinical and Translational Science

    Accepted manuscript online: 3 FEB 2016, Paulina Selaru, Yiyun Tang, Bo Huang, Anna Polli, Keith D. Wilner, Erling Donnelly and Darrel P. Cohen

    DOI: 10.1111/cts.12388

  16. Computational Investigation and Experimental Validation of Crizotinib Resistance Conferred by C1156Y Mutant Anaplastic Lymphoma Kinase

    Molecular Informatics

    Volume 34, Issue 2-3, February 2015, Pages: 105–114, Anish Kumar, V. Shanthi and K. Ramanathan

    Article first published online : 30 JAN 2015, DOI: 10.1002/minf.201400070

  17. Presence of anaplastic lymphoma kinase translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series

    Head & Neck

    Volume 37, Issue 5, May 2015, Pages: E66–E69, Sung Min Kim, Moon Jin Kim, Hyun Ae Jung, Jong-Mu Sun, Yoon-La Choi, Young-Hyeh Ko, Keunchil Park, Chung-Hwan Baek, Young-Ik Son and Myung-Ju Ahn

    Article first published online : 29 MAR 2015, DOI: 10.1002/hed.23884

  18. You have full text access to this OnlineOpen article
    Crizotinib versus platinum-based double-agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase-positive lung adenocarcinoma

    Thoracic Cancer

    Volume 7, Issue 1, January 2016, Pages: 3–8, Quan Zhang, Na Qin, Jinghui Wang, Jialin Lv, Xinjie Yang, Xi Li, Jingying Nong, Hui Zhang, Xinyong Zhang, Yuhua Wu and Shucai Zhang

    Article first published online : 23 APR 2015, DOI: 10.1111/1759-7714.12264

  19. You have free access to this content
    Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib

    Cancer

    Volume 120, Issue 5, 1 March 2014, Pages: 664–674, Evelyn M. Brosnan, Andrew J. Weickhardt, Xian Lu, Delee A. Maxon, Anna E. Barón, Michel Chonchol and D. Ross Camidge

    Article first published online : 20 NOV 2013, DOI: 10.1002/cncr.28478

  20. You have full text access to this OnlineOpen article
    In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line

    Cancer Science

    Volume 106, Issue 3, March 2015, Pages: 244–252, Shigeki Nanjo, Takayuki Nakagawa, Shinji Takeuchi, Kenji Kita, Koji Fukuda, Mitsutoshi Nakada, Hisanori Uehara, Hiroshi Nishihara, Eiji Hara, Hidetaka Uramoto, Fumihiro Tanaka and Seiji Yano

    Article first published online : 17 FEB 2015, DOI: 10.1111/cas.12600